Syrhatech raises CHF 4.5 million to innovate in hyaluronic acid medical devices

Geneva-based Syrhatech has raised CHF 4.5 million to expand its R&D and manufacturing of injectable hyaluronic acid-based medical devices to support growing demand in dermatology, orthopedics, and ophthalmology.

French-Swiss company Syrhatech has announced the successful closing of a CHF 4.5 million financing round, backed by strategic investors. Headquartered in Plan-les-Ouates in Geneva with manufacturing operations in Chambéry, France, the company is a Contract Development and Manufacturing Organization (CDMO) specializing in injectable medical devices based on hyaluronic acid (HA) and other biopolymers.

This new investment marks a key milestone for Syrhatech as it accelerates its expansion across both research and production. The funds will be used to strengthen its Geneva-based R&D team and to install new production capacity at the Chambéry facility. These developments aim to meet growing global demand for injectable HA products in sectors such as aesthetic dermatology, orthopedics, and ophthalmology, with additional therapeutic areas expected to follow.

Founded in 2015, Syrhatech has emerged as a key player in Europe’s medical device landscape, thanks to its proprietary INTEXHYA technology and a strong commitment to quality. Operating under ISO 13485 certification, the company offers end-to-end development services, from formulation and analytical testing to sterile manufacturing. Recent investments in advanced infrastructure, including the installation of a new autoclave, further underline Syrhatech’s readiness for industrial scale-up.

This funding round also presents an opportunity for investors to support a high-potential company at the intersection of biotechnology and medtech. As demand for HA-based injectable products continues to rise, driven by demographic shifts and innovation in therapeutic applications, Syrhatech is well positioned to capitalize on the trend through both its scientific expertise and manufacturing agility.

With this financing, Syrhatech strengthens its position as a European innovation hub for injectable biomaterials. By expanding both its Geneva and Chambéry sites, the company reinforces the cross-border dynamics of Western Switzerland’s life sciences ecosystem and exemplifies the region’s ability to foster agile, export-ready medtech companies.